Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264517 | PMC |
| http://dx.doi.org/10.1016/j.jfo.2021.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corneal Confocal and Specular Microscopic Characteristics in Primary Open-Angle Glaucoma: An Optical Coherence Tomography (OCT)-Based Case-Control Study.
Cureus
December 2024
Cornea and Refractive Surgery, Al-Shifa Trust Eye Hospital, Rawalpindi, PAK.
Background: Glaucoma, particularly open-angle glaucoma (OAG), is a leading cause of irreversible blindness, associated with optic nerve damage, retinal ganglion cell death, and visual field defects. Corneal biomechanical properties and cellular components, such as corneal nerve and keratocyte densities assessed by in vivo confocal microscopy (IVCM), may serve as biomarkers for glaucoma progression. This study aimed to explore the relationship between corneal nerve parameters, keratocyte density, and optical coherence tomography (OCT)-derived retinal nerve fiber layer (RNFL) thickness in primary open-angle glaucoma (POAG) patients and controls.
View Article and Find Full Text PDFCorrelation Between the Ratio of Uric Acid to High-Density Lipoprotein Cholesterol (UHR) and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus:A Cross-Sectional Study.
Diabetes Metab Syndr Obes
January 2025
Department of Endocrinology and Metabolism, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang City, People's Republic of China.
Background/objective: Considering the uncertain relationship between high-density lipoprotein cholesterol (HDL-C) and uric acid (UA) with diabetic retinopathy (DR),this study investigates the link between Uric Acid to High-Density Lipoprotein Cholesterol (UHR) and DR in T2DM patients, evaluating its potential for DR diagnosis and early prediction.
Study Design And Data Collection: This retrospective study analyzed 1450 type 2 diabetes patients, divided into NDR and DR groups by retinal exams. We gathered demographic and clinical data, calculated UHR, and explored its correlation with DR development.
Thrombolytic efficacy and safety of recombinant scu-PA in a rabbit retinal vein occlusion model.
Eur J Pharmacol
January 2025
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital. Electronic address:
Retinal vein occlusion (RVO) has become the second most common retinal vascular disease after diabetic retinopathy. Existing therapeutic approaches, including intravitreal injection of antivascular endothelial growth factors (anti-VEGFs) and/or glucocorticoids and laser therapy, primarily address secondary macular edema and neovascularisation. However, these strategies do not address the underlying cause of the disease and may have harmful side effects.
View Article and Find Full Text PDFArctiin suppress Th17 cells response and ameliorates experimental autoimmune uveitis through JAK/STAT signaling.
Cell Immunol
January 2025
Department of Rheumatology, Jincheng People 's Hospital, Shanxi Province, China.
Conventional treatments for autoimmune uveitis, such as corticosteroids and systemic immunosuppressants, often result in adverse side effects, prompting the need for therapies targeting specific molecular pathways. This study investigates the effects of Arctiin, known for its diverse biological properties, on experimental autoimmune uveitis (EAU) through its action on Th17 cells and the JAK/STAT signaling pathway. Our findings reveal that Arctiin significantly alleviates EAU by reducing clinical scores, inflammatory cell infiltration, and levels of inflammatory cytokines like IL-17 and TNF-α in the eye.
View Article and Find Full Text PDFThe Diagnosis and Treatment of Branch Retinal Vein Occlusions: An Update.
Biomedicines
January 2025
Department of Ophthalmology, "Victor Babeş" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Branch retinal vein occlusion (BRVO) is a common retinal vascular condition and a significant contributor to vision loss worldwide, particularly in middle-aged and elderly populations. This review synthesizes current knowledge on the epidemiology, pathogenesis, and clinical features of BRVO, alongside recent advancements in diagnostic and therapeutic strategies. BRVO is approximately four times more prevalent than central retinal vein occlusion (CRVO) and often leads to significant vision impairment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!